BioSpace News Archive

Lantheus Holdings, Inc. announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating results for the fourth quarter and full year of 2019.

Kannalife, Inc. announced that China has issued the Company, Chinese Patent CN106456573B specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” which further bolsters the Company’s global patent portfolio of cannabidiol -like molecules.

Two additional published studies highlight WatchPAT’s accuracy and effectiveness in patients with Central Sleep Apnea (CSA) and Chronic Obstructive Pulmonary Disease (COPD) CAESAREA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced publication of results of the COMPASS s

MannKind Corporation will release its 2019 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM on Tuesday, February 25, 2020.

Shanghai Henlius Biotech, Inc. (2696.HK, Henlius), a global biologics company specialized in the discovery and development of high-quality and affordable antibodies for the treatment of patients with cancer and autoimmune diseases, recently held its fourth Scientific Advisory Board (SAB) meeting at Bay Area where the United States (US) Research and Development (R&D) site is located.

CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the release of the company’s 2020 Vision Report.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis

Imprivata®, the digital identity company for healthcare, today announced that it was named to the Constellation ShortList™ for Healthcare Medical Device Security in Q1 2020.

VolitionRx Limited announced that research on its Nu.Q Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform.